Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$0.43 USD
+0.01 (2.79%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.42 -0.01 (-1.57%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLSD 0.43 +0.01(2.79%)
Will CLSD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLSD
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Other News for CLSD
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
CLSD Gains Health Canada Approval for XIPERE in Uveitic Macular Edema | CLSD Stock News